CL2012000795A1 - Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak); composicion farmaceutica que comprnde a uno de dichos compuestos; y su uso para la preparacion de medicamentos utiles en el tratamiento de alzheimer, cancer, artritis, leucemia, diabetes, enfermedades inflamatorias y autoinmunes, entre otras. - Google Patents

Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak); composicion farmaceutica que comprnde a uno de dichos compuestos; y su uso para la preparacion de medicamentos utiles en el tratamiento de alzheimer, cancer, artritis, leucemia, diabetes, enfermedades inflamatorias y autoinmunes, entre otras.

Info

Publication number: CL2012000795A1
Authority: CL; Chile
Prior art keywords: compounds; jak; pyrrolo; alzheimer; leukemia
Prior art date: 2009-10-15

Application number

CL2012000795A

Other languages

English (en)

Spanish (es)

Inventor

Brad Alan Acker

Susan J Hartmann

Horng-Chin Huang

Eric Jon Jacobsen

Michele Ann Promo

Sergey Gregory Wolfson

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-15

Filing date

2012-03-30

Publication date

2012-09-07

2012-03-30 Application filed by Pfizer filed Critical Pfizer

2012-09-07 Publication of CL2012000795A1 publication Critical patent/CL2012000795A1/es

Links

150000001875 compounds Chemical class 0.000 title abstract 3
JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 title abstract 2
102000015617 Janus Kinases Human genes 0.000 title abstract 2
108010024121 Janus Kinases Proteins 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 title abstract 2
206010003246 arthritis Diseases 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
206010012601 diabetes mellitus Diseases 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
208000032839 leukemia Diseases 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
208000023275 Autoimmune disease Diseases 0.000 title 1
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
208000027866 inflammatory disease Diseases 0.000 title 1
230000002757 inflammatory effect Effects 0.000 title 1
206010025323 Lymphomas Diseases 0.000 abstract 1
208000024799 Thyroid disease Diseases 0.000 abstract 1
230000001363 autoimmune Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Virology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2012000795A 2009-10-15 2012-03-30 Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak); composicion farmaceutica que comprnde a uno de dichos compuestos; y su uso para la preparacion de medicamentos utiles en el tratamiento de alzheimer, cancer, artritis, leucemia, diabetes, enfermedades inflamatorias y autoinmunes, entre otras. CL2012000795A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US25203909P	2009-10-15	2009-10-15

Publications (1)

Publication Number	Publication Date
CL2012000795A1 true CL2012000795A1 (es)	2012-09-07

Family

ID=43413616

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012000795A CL2012000795A1 (es)	2009-10-15	2012-03-30	Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak); composicion farmaceutica que comprnde a uno de dichos compuestos; y su uso para la preparacion de medicamentos utiles en el tratamiento de alzheimer, cancer, artritis, leucemia, diabetes, enfermedades inflamatorias y autoinmunes, entre otras.

Country Status (29)

Country	Link
US (1)	US8633206B2 (2)
EP (1)	EP2488524B1 (2)
JP (1)	JP5629324B2 (2)
KR (1)	KR20120083452A (2)
CN (1)	CN102574860A (2)
AP (1)	AP2012006192A0 (2)
AR (1)	AR078635A1 (2)
AU (1)	AU2010308028A1 (2)
CA (1)	CA2776028C (2)
CL (1)	CL2012000795A1 (2)
CO (1)	CO6531451A2 (2)
CR (1)	CR20120164A (2)
CU (1)	CU20120059A7 (2)
DO (1)	DOP2012000080A (2)
EA (1)	EA201290147A1 (2)
EC (1)	ECSP12011855A (2)
ES (1)	ES2426407T3 (2)
IL (1)	IL218802A0 (2)
IN (1)	IN2012DN02577A (2)
MA (1)	MA33670B1 (2)
MX (1)	MX2012004379A (2)
NI (1)	NI201200053A (2)
PE (1)	PE20121077A1 (2)
PH (1)	PH12012500583A1 (2)
TN (1)	TN2012000146A1 (2)
TW (1)	TWI398444B (2)
UY (1)	UY32947A (2)
WO (1)	WO2011045702A1 (2)
ZA (1)	ZA201202718B (2)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2572826C2 (ru)	2008-12-02	2016-01-20	Чиралджен, Лтд.	Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
AP3280A (en)	2009-03-23	2015-05-31	Glenmark Pharmaceuticals Sa	Fused pyrimidine-dione derivatives as TRPA1 modulators
PT2411395E (pt)	2009-03-23	2013-06-06	Glenmark Pharmaceuticals Sa	Derivados de furopirimidinadiona como moduladores de trpa1
CA2767253A1 (en)	2009-07-06	2011-01-13	Ontorii, Inc.	Novel nucleic acid prodrugs and methods of use thereof
TW201111385A (en) *	2009-08-27	2011-04-01	Biocryst Pharm Inc	Heterocyclic compounds as janus kinase inhibitors
ES2461967T3 (es) *	2009-12-18	2014-05-21	Pfizer Inc.	Compuestos de pirrolo[2,3-d]pirimidina
JP5868324B2 (ja)	2010-09-24	2016-02-24	株式会社Wave Life Sciences Japan	不斉補助基
AU2012284265B2 (en)	2011-07-19	2017-08-17	Wave Life Sciences Ltd.	Methods for the synthesis of functionalized nucleic acids
AU2012295802B2 (en)	2011-08-12	2017-03-30	Nissan Chemical Industries, Ltd.	Tricyclic heterocyclic compounds and JAK inhibitors
CN104684923B (zh)	2012-07-13	2018-09-28	株式会社新日本科学	手性核酸佐剂
JP6453212B2 (ja)	2012-07-13	2019-01-16	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	キラル制御
SG11201500239VA (en)	2012-07-13	2015-03-30	Wave Life Sciences Japan	Asymmetric auxiliary group
KR102127939B1 (ko) *	2012-07-17	2020-06-29	글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드	선택적인 안드로겐 수용체 조절제로서의 인돌카르보니트릴
CN103896946B (zh) *	2012-12-28	2018-04-03	浙江导明医药科技有限公司	用于预防及治疗多种自身免疫疾病的新化合物
EP2951590A1 (en)	2013-02-04	2015-12-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for assaying jak2 activity in red blood cells and uses thereof
JP6248948B2 (ja)	2013-02-08	2017-12-20	日産化学工業株式会社	３環性ピロロピリジン化合物及びｊａｋ阻害剤
CU24275B1 (es) *	2013-02-22	2017-10-05	Pfizer	Derivados de cicloalquilo pirrolo [2,3-d] pirimidina-4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos
WO2014177527A1 (en)	2013-05-02	2014-11-06	F. Hoffmann-La Roche Ag	Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
WO2015108047A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108046A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108048A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
ES2917473T3 (es)	2014-01-16	2022-07-08	Wave Life Sciences Ltd	Diseño quiral
EP2924026A1 (en)	2014-03-28	2015-09-30	Novartis Tiergesundheit AG	Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2015174376A1 (ja)	2014-05-14	2015-11-19	日産化学工業株式会社	３環性化合物及びｊａｋ阻害剤
EP3180344B1 (en)	2014-08-12	2019-09-18	Pfizer Inc	Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US9926327B2 (en) *	2016-02-16	2018-03-27	Zoetis Services Llc	Process for preparing 7H-pyrrolo[2,3-D]pyrimidine compounds
CN107098908B (zh) *	2016-02-23	2021-01-08	欣凯医药科技(上海)有限公司	一种吡咯并嘧啶类化合物的制备方法和应用
WO2018167283A1 (en)	2017-03-17	2018-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en)	2017-04-13	2018-10-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2020092015A1 (en)	2018-11-02	2020-05-07	University Of Rochester	Therapeutic mitigation of epithelial infection
WO2020155931A1 (zh)	2019-01-30	2020-08-06	格格巫（珠海）生物科技有限公司	一种jak抑制剂及其制备方法
IL264854A (en) *	2019-02-14	2020-08-31	Bahat Anat	Spt5 inhibitors and methods of use thereof
WO2021003084A1 (en) *	2019-07-01	2021-01-07	Ligang Qian	P2x7r antagonists
AU2020338043B2 (en) *	2019-08-26	2025-12-18	Chemwerth, Inc.	Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl)amino compounds useful as JAK1 inhibitors
CN114761013A (zh)	2019-09-27	2022-07-15	迪斯克医药公司	治疗骨髓纤维化和相关病症的方法
WO2021231798A1 (en)	2020-05-13	2021-11-18	Disc Medicine, Inc.	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN115246833B (zh) *	2021-04-27	2024-08-13	洛阳惠中兽药有限公司	一种奥拉替尼化合物及其中间体化合物的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
BR9911365A (pt)	1998-06-19	2001-03-13	Pfizer Prod Inc	Compostos pirrolo[2,3-d]pirimidina
EP1382339B1 (en)	1999-12-10	2007-12-05	Pfizer Products Inc.	Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
IL152771A0 (en) *	2000-06-26	2003-06-24	Pfizer Prod Inc	PYRROLO(2,3-d) PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
KR100678800B1 (ko)	2002-11-21	2007-02-05	화이자 프로덕츠 인코포레이티드	3-아미노-피페리딘 유도체 및 그의 제조 방법
EP1663204B1 (en) *	2003-08-29	2014-05-07	Exelixis, Inc.	C-kit modulators and methods of use
CA2546192C (en)	2003-11-17	2010-04-06	Pfizer Products Inc.	Pyrrolopyrimidine compounds useful in treatment of cancer
JP2007526906A (ja)	2004-03-05	2007-09-20	大正製薬株式会社	ピロロピリミジン誘導体
CA2572331A1 (en) *	2004-07-02	2006-02-09	Exelixis, Inc.	C-met modulators and method of use
AR054416A1 (es) *	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006133426A2 (en)	2005-06-08	2006-12-14	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
EP2251341A1 (en)	2005-07-14	2010-11-17	Astellas Pharma Inc.	Heterocyclic Janus kinase 3 inhibitors
BRPI0613876A2 (pt)	2005-07-29	2011-02-15	Pfizer Prod Inc	derivados de pirrolo [2,3-d] pirimidina; seus intermediários e sìntese
ZA200802685B (en)	2005-09-30	2009-10-28	Vertex Pharma	Deazapurines useful as inhibitors of janus kinases
CN103626742B (zh)	2005-11-01	2017-04-26	塔格根公司	激酶的联-芳基间-嘧啶抑制剂
CA2642229C (en)	2006-02-24	2015-05-12	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
EP1990335A4 (en) *	2006-03-02	2009-11-11	Astellas Pharma Inc	17-BETA-HSD-type-5 INHIBITOR
WO2009049028A1 (en)	2007-10-09	2009-04-16	Targegen Inc.	Pyrrolopyrimidine compounds and their use as janus kinase modulators
WO2009115084A2 (de)	2008-03-20	2009-09-24	Schebo Biotech Ag	Neue pyrrolopyrimidin-derivate und deren verwendungen
JP4884570B2 (ja) *	2008-08-20	2012-02-29	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジン化合物

2010
- 2010-10-01 CA CA2776028A patent/CA2776028C/en not_active Expired - Fee Related
- 2010-10-01 MX MX2012004379A patent/MX2012004379A/es unknown
- 2010-10-01 ES ES10771200T patent/ES2426407T3/es active Active
- 2010-10-01 AP AP2012006192A patent/AP2012006192A0/xx unknown
- 2010-10-01 PE PE2012000447A patent/PE20121077A1/es not_active Application Discontinuation
- 2010-10-01 KR KR1020127012417A patent/KR20120083452A/ko not_active Ceased
- 2010-10-01 PH PH1/2012/500583A patent/PH12012500583A1/en unknown
- 2010-10-01 WO PCT/IB2010/054447 patent/WO2011045702A1/en not_active Ceased
- 2010-10-01 IN IN2577DEN2012 patent/IN2012DN02577A/en unknown
- 2010-10-01 EA EA201290147A patent/EA201290147A1/ru unknown
- 2010-10-01 JP JP2012533715A patent/JP5629324B2/ja not_active Expired - Fee Related
- 2010-10-01 EP EP10771200.2A patent/EP2488524B1/en active Active
- 2010-10-01 CN CN2010800461239A patent/CN102574860A/zh active Pending
- 2010-10-01 AU AU2010308028A patent/AU2010308028A1/en not_active Abandoned
- 2010-10-12 TW TW099134779A patent/TWI398444B/zh not_active IP Right Cessation
- 2010-10-13 US US12/903,554 patent/US8633206B2/en active Active
- 2010-10-14 AR ARP100103751A patent/AR078635A1/es not_active Application Discontinuation
- 2010-10-15 UY UY0001032947A patent/UY32947A/es not_active Application Discontinuation
2012
- 2012-03-22 IL IL218802A patent/IL218802A0/en unknown
- 2012-03-23 DO DO2012000080A patent/DOP2012000080A/es unknown
- 2012-03-29 TN TNP2012000146A patent/TN2012000146A1/fr unknown
- 2012-03-30 CL CL2012000795A patent/CL2012000795A1/es unknown
- 2012-03-30 CR CR20120164A patent/CR20120164A/es unknown
- 2012-04-09 NI NI201200053A patent/NI201200053A/es unknown
- 2012-04-13 MA MA34774A patent/MA33670B1/fr unknown
- 2012-04-13 CU CU20120059A patent/CU20120059A7/es unknown
- 2012-04-13 ZA ZA2012/02718A patent/ZA201202718B/en unknown
- 2012-04-18 CO CO12064126A patent/CO6531451A2/es not_active Application Discontinuation
- 2012-04-27 EC ECSP12011855 patent/ECSP12011855A/es unknown

Also Published As

Publication number	Publication date
US8633206B2 (en)	2014-01-21
EA201290147A1 (ru)	2012-11-30
ECSP12011855A (es)	2012-06-29
MA33670B1 (fr)	2012-10-01
CR20120164A (es)	2012-11-07
AR078635A1 (es)	2011-11-23
CU20120059A7 (es)	2012-06-29
CN102574860A (zh)	2012-07-11
TN2012000146A1 (fr)	2013-09-19
UY32947A (es)	2011-05-31
JP5629324B2 (ja)	2014-11-19
MX2012004379A (es)	2012-06-01
NI201200053A (es)	2012-08-09
EP2488524A1 (en)	2012-08-22
IN2012DN02577A (2)	2015-08-28
EP2488524B1 (en)	2013-07-03
PH12012500583A1 (en)	2012-10-22
US20110136765A1 (en)	2011-06-09
KR20120083452A (ko)	2012-07-25
ES2426407T3 (es)	2013-10-23
JP2013508266A (ja)	2013-03-07
IL218802A0 (en)	2012-06-28
TWI398444B (zh)	2013-06-11
AU2010308028A1 (en)	2012-04-19
DOP2012000080A (es)	2012-06-15
AP2012006192A0 (en)	2012-04-30
WO2011045702A1 (en)	2011-04-21
CA2776028A1 (en)	2011-04-21
TW201125866A (en)	2011-08-01
CO6531451A2 (es)	2012-09-28
ZA201202718B (en)	2012-12-27
CA2776028C (en)	2015-12-01
PE20121077A1 (es)	2012-08-10

Similar Documents

Publication	Publication Date	Title
CL2012000795A1 (es)	2012-09-07	Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak); composicion farmaceutica que comprnde a uno de dichos compuestos; y su uso para la preparacion de medicamentos utiles en el tratamiento de alzheimer, cancer, artritis, leucemia, diabetes, enfermedades inflamatorias y autoinmunes, entre otras.
CL2008001709A1 (es)	2008-11-03	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
CL2011000668A1 (es)	2011-10-28	Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
CL2007003774A1 (es)	2008-04-18	Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
CL2008000670A1 (es)	2008-11-03	Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
CL2013001412A1 (es)	2013-12-20	Compuestos derivados de pirrolo[2,3-b]piridina y de pirrolo[2,3-d]pirimidina sustituidos con ciclobutilo; inhibidores de jaks; composicion farmaceutica que lo comprende; utiles en el tratamiento de enfermedades autoinmunes, cancer, un trastorno mieloproliferativo, enfermedades inflamatorias, entre otras.
CL2008000790A1 (es)	2008-05-30	Compuestos derivados de purina sustituida; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como aterosclerosis, artritis, psoriasis y cancer.
CL2007001166A1 (es)	2008-01-25	Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica
CL2008001632A1 (es)	2009-10-16	Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
CL2007001167A1 (es)	2008-01-25	Compuestos derivados de pirimidina condensada, inhibidores de p13-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicionfarmaceutica.
CL2012001073A1 (es)	2012-10-26	Compuestos derivados de pirido[4,3-d]pirimidin-5-ona, sus composiciones farmaceuticas y su uso como inhibidores de quinasa para tratar asma, epoc, colitis ulcerante, bronquitis, lupus, cancer de mamas, enfermedad de alzheimer, enfermedad de parkinson, osteoporosis, esclerosis multiple, diabetes, trastornos oculares, restenosis, enfermedades inflamatorias.
CL2008003506A1 (es)	2009-01-09	Compuestos derivados de pirrolo[3,2-d]pirimidina, inhibidores de quinasa pi3 y quinasa mtor; metodo de preparacion; composicion farmaceutica, util para el tratamiento de enfermedades tales como aterosclerosis, artritis, psoriasis y cancer.
CL2009001212A1 (es)	2009-10-23	Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
PH12013500299B1 (en)	2019-03-08	Pyrrolopyrimidine compounds and uses thereof
BR112013033182A2 (pt)	2016-09-06	compostos imidazopiridinil-aminopiridina substituída
CL2012003381A1 (es)	2013-03-22	Compuestos derivados de 4-amino-3-fenil-1h-pirazolo[3,4-d]pirimidina; y compuesto (r)-1-(3-(4-amino-3-(4-fenoxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona para tratar el linfoma no hodgkin recurrente o resistente al tratamiento en un individuo; y uso de combinaciones con un segundo medicamento para el cancer.
MX2019003605A (es)	2019-06-17	Formas solidas de un inhibidor de cdk4/6 selectivo.
CL2008000348A1 (es)	2008-08-18	Compuestos derivados de carboxamida, inhibidores de la actividad de la proteina quinasa b; composicion farmaceutica; proceso para prepararla; y uso en el tratamiento de enfermedades tales como cancer y artritis.
CL2009000255A1 (es)	2009-08-14	Compuestos derivados de pirrolo [2,3-d] pirimidinas, con actividad inhibidora de cinasa jak1, jak2 y jak3; composicion farmaceutica; utiles en el tratamiento de enfermedades proliferativas, rechazo a trasplantes, lupus eritematoso, esclerosis multiple, artritis reumatoide, entre otras.
CL2008001374A1 (es)	2008-11-14	Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
CL2010001637A1 (es)	2011-07-15	Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
CL2014002301A1 (es)	2015-05-08	Compuestos derivados de pirimidin piridinas sustituidas, inhibidores de serina/treonina cinasas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento de una enfermedad hiperproliferativa tal como melanoma, cancer, leucemias y una enfermedad inflamatoria como artritis y reumatismo entre otras.
CL2012001627A1 (es)	2012-10-05	Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
BR112015009942A2 (pt)	2017-07-11	derivados de tiofeno fundidos tricíclicos como inibidores de jak
CL2012001180A1 (es)	2013-01-25	Compuestos derrivados de pirrolo[2,3-b]piridina; inhibidores de cinasa-fms; metodo de preparacion de los compuestos; composicion y combinacion farmaceutica que los comprende; kit que incluye al compuesto o composicion; y uso en el tratamiento de enfermedades tales como tumores de celulas mamarias, cancer de prostata, alzheimer, entre otras.